论文部分内容阅读
目的探讨格列酮类药物(Thiazolidinediones,TZDs)可以阻止或延缓肾脏纤维化的进展。方法 40只SD雄性大鼠随机分为三组:正常对照组(N组)、ADR模型组(M组)和RSG治疗(T组),全自动生化分析仪检测大鼠血清生化指标,采用磺基水杨酸比浊法测定尿蛋白。结果 M组大鼠出现大量蛋白尿及高脂血症、低蛋白血症;T组大鼠肾脏病理损害有不同程度减轻。结论罗格列酮(RSG)可以减少阿霉素(ADR)诱导的慢性肾损害大鼠的尿蛋白排泄,减轻其肾脏病理损害程度。
Objective To investigate the effects of thiazolidinediones (TZDs) on the progression of renal fibrosis. Methods Forty SD male rats were randomly divided into three groups: normal control group (N group), ADR model group (M group) and RSG treatment group (T group), serum biochemical indexes were detected by automatic biochemical analyzer, Determination of urinary protein by turbidimethylsalicylic acid method. Results A large number of proteinuria, hyperlipidemia and hypoalbuminemia occurred in M group rats, while renal pathological changes in T group were alleviated to some extent. Conclusion Rosiglitazone (RSG) can reduce urinary protein excretion and reduce the degree of renal pathological damage induced by adriamycin (ADR) in rats with chronic renal impairment.